



ASX ANNOUNCEMENT

16 December 2019

Resignation of Neil Belot as director

16 December 2019– Cann Group Limited (ASX: CAN) announced today that Mr Neil Belot has resigned as non-executive director of the Company effective 14 December 2019.

Mr Belot was appointed to the Board of the Company on 26 February 2018. He was an employee of Aurora Cannabis Inc. (**Aurora**), the Company's largest shareholder. Mr Belot resigned from his employment at Aurora with effect on 14 December 2019 (Australian time). Aurora is nominating a person to fill the casual vacancy left by Mr Belot's resignation.

As the holder of a medicinal cannabis licence, a cannabis research licence and a manufacturing licence under the Narcotic Drugs Act, the Company is required to notify the Office of Drug Control (**ODC**) of any change or proposed change to the directors of the company to allow the ODC to assess the suitability of the replacement director.

Once this review has completed, and subject to a satisfactory outcome, the replacement non-executive director will be appointed to the Board of the Company and a further announcement will be made at that time.

Geraldine Farrell
Company Secretary
Cann Group Limited

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@cann grouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 498 000 762
clive.fanning@cann grouplimited.com

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia's first medicinal cannabis research licence in February 2017, in addition to Australia's first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada's largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.5% shareholding.